Dapirolizumab pegol
| Disease area studied | Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Systemic Lupus Erythematosus | A Phase 2b, randomized, double-blind, PBO-controlled, parallel-group, dose-ranging study followed by an observational period that will evaluate the efficacy of Dapirolizumab Pegol (DZP) in inducing disease control and the safety of DZP in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE) who are receiving standard-of-care medications. | Phase 2 |
SL0023
Completed |
NCT02804763 2015-004457-40 |
LINK
|
Stach C., et al. Lupus Sci Med 2023; 10(Suppl 1):A163-A164 Post hoc analysis : Askanase A., et al. Arthritis Rheumatol 2023; 75(Suppl. 9):4622–4 Stach C., et al. Arthritis Rheumatol 2023; 75(Suppl. 9):2965–7 Cutcutache I., et al. Arthritis Rheumatol 2023; 75(Suppl. 9):4624–6 | |
| Systemic Lupus Erythematosus | The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. | Phase 3 |
SL0043
Completed |
NCT04294667 2019-003406-27 |
|||
| Systemic Lupus Erythematosus | A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus | Phase 3 |
SL0046
Ongoing |
NCT04976322 2019-003409-83 2023-506368-14-00 |